Beyond its effects on CLL cells, BTK inhibition can impair NK cell function and reduce the production of pro-inflammatory cytokines, such as tumor necrosis factor-α and IL-1β, leading to diminished activity of macrophages and neutrophils. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.